Shots:

• The purpose of the switching study (AVT02-GL-302) is to support the approval of AVT02 in the US as an interchangeable biosimilar product with the high concentration (100mg/mL) dosage forms of Humira. The results of the study are expected in late 2021
• In May’21- Alvotech sued to end AbbVie’s wrongful monopoly on Humira and bring an affordable arthritis treatment to the US
• In Nov’20- the US FDA and EMA has accepted Alvotech’s regulatory submissions for AVT02. The company expects FDA’s decision in Sept’2021 and EMA’s decision in Q4’21

  | Ref: BUSINESS WIRE | Image: BUSINESS WIRE